Clindamycin Palmitate

Summary

Clindamycin Palmitate (CHEMBL1201289) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 663.4 Da · C34H63ClN2O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201289
Name	Clindamycin Palmitate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16052039
Molecular formula	C34H63ClN2O6S
Molecular weight	663.4
InChIKey	OYSKUZDIHNKWLV-PRUAPSLNSA-N

SMILES: CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1SC)[C@@H]([C@H](C)Cl)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O

IUPAC name: [(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] hexadecanoate

Also known as: Clindamycin palmitate, CLINDAMYCIN PALMITATE, Clindamycin palmitate HCl

Parent form; salt/anhydrous children: CHEMBL1200632

Patent coverage: 1 distinct patent families (3 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03080740	PHASE4	UNKNOWN	The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).